|
Synonyms: OMP-52M51 | OMP52M51
Compound class:
Antibody
Comment: Brontictuzumab (OMP-52M51) is a fully human anti-NOTCH1 monoclonal antibody [4-5]. It was developed by OncoMed Pharmaceuticals. Peptide sequence analysis reveals that the heavy and light chains that make up brontictuzumab are claimed in Oncomed patent US20140011271A1 [3]. The heavy chain is SEQ ID NO:22 (52M51-H4), and the light chain is SEQ ID NO:26 (2M51L3), making the brontictuzumab structure 52M51H4L3.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Brontictuzumab (OMP-52M51) was advanced to early phase clinical studies to determine its potential to treat advanced lymphoid and solid malignancies [2]. As of January 2021 there were no active trials on ClinicalTrials.gov. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01778439 | A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | Phase 1 Interventional | Mereo BioPharma | Target engagement was confirmed in this study, and an efficacy signal was detected in participants with adenoid cystic carcinoma and NOTCH1 pathway activation. | 1 |
